Dermagraft-TC: Difference between revisions
mNo edit summary |
mNo edit summary |
||
| Line 7: | Line 7: | ||
| first= | | first= | ||
| publisher=Advanced Biohealing, Inc. | | publisher=Advanced Biohealing, Inc. | ||
| | | website= | ||
| date= | | date= | ||
| accessdate=2011-03-06 | | accessdate=2011-03-06 | ||
| Line 17: | Line 17: | ||
| first= | | first= | ||
| publisher=MediLexicon | | publisher=MediLexicon | ||
| | | website= | ||
| date= | | date= | ||
| accessdate=2011-03-06 | | accessdate=2011-03-06 | ||
| Line 30: | Line 30: | ||
| quote=...the Food and Drug Administration has approved Dermagraft-TC for marketing, making it the first human fibroblast-derived temporary skin substitute to be approved. | | quote=...the Food and Drug Administration has approved Dermagraft-TC for marketing, making it the first human fibroblast-derived temporary skin substitute to be approved. | ||
| accessdate=2011-03-06 | | accessdate=2011-03-06 | ||
}}</ref> and it sells for about $3,000 per square foot; one foreskin contains enough genetic material to grow 250,000 square feet of skin.<ref> | }}</ref> and it sells for about $3,000 per square foot; one foreskin contains enough genetic material to grow 250,000 square feet of skin.<ref>{{REFjournal | ||
| last=Daecher | |||
| first=M. | |||
| coauthors= | |||
| title=Circumcision | |||
| journal=Icon | |||
| date=1998 | |||
| volume=2 | |||
| issue=2 | |||
| pages=70-73 | |||
| url= | |||
| quote= | |||
| pubmedID= | |||
| pubmedCID= | |||
| DOI= | |||
| accessdate= | |||
}}</ref> | |||
{{REF}} | {{REF}} | ||